Product Images Praluent

This looks like a graph/chart that illustrates the mean percent change in LDL-C from baseline over time for two groups of individuals receiving different treatments. The two groups are labeled "PRALUENT" and "Placebo." The x-axis shows time in weeks, and the y-axis shows the percent change in LDL-C. The graph shows that PRALUENT had a greater reduction in LDL-C compared to Placebo over the course of the study.*

The text seems to be a graph with two lines representing the mean percent change in LDL-C (a type of cholesterol) from baseline at different time points (weeks) for two treatments: Placebo and PRALUENT. The x-axis shows the time points in weeks and the y-axis shows the mean percent change from baseline. The PRALUENT line appears to decrease more rapidly than the Placebo line, indicating that PRALUENT is more effective at reducing LDL-C levels over time.*

This is a chart showing the LDL-C LS mean percent change from baseline over time points in weeks. The chart includes data for a placebo group, a Praluent75 Q2W group, and a Praluent 300 Q4W group. The x-axis represents the time points (in weeks), and the y-axis represents the percent change from baseline.*

This is a table showing the mean percent change from baseline of LDL-C levels at different time points (4, 8, and 12 weeks) for a group of 45 patients treated with PRALUENT 150 mg Q2W and a group of 24 patients treated with a placebo.*

This description is not sufficient to generate a useful description.*

This text is not available as it only contains non-English characters and a few symbols.*

This is a prompt or command that instructs someone to release a button right away.*

Praluent is a medication that is available in the form of an injection. Each pre-filled pen of Praluent contains 75mg alirocumab and is intended for single-dose, subcutaneous injection. In addition to alirocumab, the pen contains histidine, polysorbate 20, sucrose, and water. Caution must be taken to keep Praluent out of reach of children and to avoid use if the seal is broken or the package is damaged. Patients should consult the package insert for dosage information and administration instructions. Praluent must be kept refrigerated between 2°C to 8°C, with proper protection from light, and should not be frozen or exposed to extreme temperatures or shaken. If necessary, the medication can be stored at room temperature up to 77°F (25°C) for a maximum of 30 days. Once removed from the refrigerator, Praluent must be used within 30 days.*

This text is a description of the drug Praluent (alirocumab) that comes in a prefilled pen for subcutaneous injection only. Each pen contains 150mg of the drug and the ingredients include histidine, polysorbate 20, sucrose, and water for injection. The drug must be stored in a refrigerator and not be frozen, exposed to extreme heat or light, or shaken. If the package is damaged, do not use it. The drug should be used within 30 days after removal from the refrigerator. The text also includes some identification codes for the drug.*